{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:21:08Z","timestamp":1771338068544,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pseudomonas aeruginosa is an opportunistic pathogen that can cause life-threatening infections in patients admitted to intensive care units. Resistance rapidly develops against two drugs of choice: ceftazidime and meropenem. Several therapeutic protocols were compared for reduction in viable cells and limiting development of resistance. Chemostat cultures were exposed to antibiotic concentrations measured in the blood of patients at low (5th percentile), medium (50th percentile) or high (95th percentile) levels in several therapy protocols to simulate therapy. Cultures exposed to ceftazidime recovered after 1 day at low, 2 days at medium and 3 days at high concentrations and developed corresponding levels of resistance. Patterns were very similar for meropenem except that recovery was delayed. Fluctuating levels and intermittent treatment achieved similar reduction of cell numbers at lower resistance costs. Treatment alternating ceftazidime and meropenem reduced cell numbers more than monotherapy, while strongly limiting resistance. Combination therapy was even more effective in both respects. Therapeutic goals are best reached with least risk of resistance when ceftazidime and meropenem are used in combination or alternating, at the highest concentrations the patient can endure. Monotherapy should also apply the highest concentration that is safe for the shortest time that achieves treatment objectives.<\/jats:p>","DOI":"10.1093\/femsle\/fnx142","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T11:10:06Z","timestamp":1498648206000},"source":"Crossref","is-referenced-by-count":10,"title":["Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections"],"prefix":"10.1093","volume":"364","author":[{"given":"Yanfang","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Microbial Food Safety, Swammerdam Institute of Life Sciences, University of Amsterdam, 1098 XH Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roosmarijn T","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbial Food Safety, Swammerdam Institute of Life Sciences, University of Amsterdam, 1098 XH Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier M","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy & Clinical Pharmacology, Academic Medical Center, Amsterdam 1105AZ, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caspar J","family":"Hodiamont","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Academic Medical Center, Amsterdam 1105AZ, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Brul","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbial Food Safety, Swammerdam Institute of Life Sciences, University of Amsterdam, 1098 XH Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Schultsz","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Academic Medical Center, Amsterdam 1105AZ, the Netherlands"},{"name":"Department of Global Health-Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam 1105AZ, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benno H","family":"ter Kuile","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbial Food Safety, Swammerdam Institute of Life Sciences, University of Amsterdam, 1098 XH Amsterdam, the Netherlands"},{"name":"Office for Risk Assessment and Research Coordination Netherlands Food and Consumer Product Safety Authority, Utrecht 3511GG, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"2019101723585872200_bib1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/jac\/dkv475","article-title":"Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli","volume":"71","author":"Adler","year":"2016","journal-title":"J Antimicrob Chemoth"},{"key":"2019101723585872200_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/0972-5229.132495","article-title":"Current concepts in combination antibiotic therapy for critically ill patients","volume":"18","author":"Ahmed","year":"2014","journal-title":"Indian J Crit Care Med"},{"key":"2019101723585872200_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0885066610371189","article-title":"Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind","volume":"25","author":"Arnold","year":"2010","journal-title":"J Intensive Care Med"},{"key":"2019101723585872200_bib4","doi-asserted-by":"crossref","first-page":"aad3292","DOI":"10.1126\/science.aad3292","article-title":"Multidrug evolutionary strategies to reverse antibiotic resistance","volume":"351","author":"Baym","year":"2016","journal-title":"Science"},{"key":"2019101723585872200_bib5","doi-asserted-by":"crossref","first-page":"e1001984","DOI":"10.1371\/journal.pmed.1001984","article-title":"The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies","volume":"13","author":"Boni","year":"2016","journal-title":"PLoS Med"},{"key":"2019101723585872200_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and evolution of antibiotic resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol Mol Biol R"},{"key":"2019101723585872200_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/AAC.01617-06","article-title":"Quinolone-mediated bacterial death","volume":"52","author":"Drlica","year":"2008","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019101723585872200_bib9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1128\/AAC.02231-15","article-title":"Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 2","volume":"60","author":"Drusano","year":"2016","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.02177-15","article-title":"Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 1","volume":"60","author":"Drusano","year":"2016","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib11","doi-asserted-by":"crossref","first-page":"e0149310","DOI":"10.1371\/journal.pone.0149310","article-title":"Development of antibiotic resistance during simulated treatment of Pseudomonas aeruginosa in chemostats","volume":"11","author":"Feng","year":"2016","journal-title":"PLoS One"},{"key":"2019101723585872200_bib12","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1128\/AAC.00434-16","article-title":"Dynamics of mutations during development of resistance by Pseudomonas aeruginosa against five antibiotics","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1128\/AAC.35.7.1284","article-title":"Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital","volume":"35","author":"Gerding","year":"1991","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib14","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.34.10.1865","article-title":"Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response","volume":"34","author":"Gilbert","year":"1990","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib15","doi-asserted-by":"crossref","first-page":"e1002158","DOI":"10.1371\/journal.ppat.1002158","article-title":"Selection of resistant bacteria at very low antibiotic concentrations","volume":"7","author":"Gullberg","year":"2011","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"2019101723585872200_bib16","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkp256","article-title":"The changing epidemiology of resistance","volume":"64","author":"Hawkey","year":"2009","journal-title":"J Antimicrob Chemoth"},{"key":"2019101723585872200_bib17","doi-asserted-by":"crossref","first-page":"204ra132","DOI":"10.1126\/scitranslmed.3006609","article-title":"Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development","volume":"5","author":"Imamovic","year":"2013","journal-title":"Sci Transl Med"},{"key":"2019101723585872200_bib18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jac\/dkr137","article-title":"Impact of antimicrobial stewardship in critical care: a systematic review","volume":"66","author":"Kaki","year":"2011","journal-title":"J Antimicrob Chemoth"},{"key":"2019101723585872200_bib19","doi-asserted-by":"crossref","first-page":"14494","DOI":"10.1073\/pnas.1409800111","article-title":"Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance","volume":"111","author":"Kim","year":"2014","journal-title":"P Natl Acad Sci USA"},{"issue":"Suppl 2","key":"2019101723585872200_bib20","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/504484","article-title":"Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit?","volume":"43","author":"Kollef","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019101723585872200_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2019101723585872200_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/dnares\/dsu032","article-title":"Genomic analysis reveals distinct concentration-dependent evolutionary trajectories for antibiotic resistance in Escherichia coli","volume":"21","author":"Mogre","year":"2014","journal-title":"DNA Res"},{"key":"2019101723585872200_bib23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/molbev\/msu191","article-title":"Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution","volume":"31","author":"Oz","year":"2014","journal-title":"Mol Biol Evol"},{"key":"2019101723585872200_bib24","doi-asserted-by":"crossref","first-page":"37853","DOI":"10.1038\/srep37853","article-title":"Optimising antibiotic usage to treat bacterial infections","volume":"6","author":"Paterson","year":"2016","journal-title":"Sci Rep"},{"key":"2019101723585872200_bib25","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance\u2013what's dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"2019101723585872200_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/molbev\/msv006","article-title":"Collateral resistance and sensitivity modulate evolution of high-level resistance to drug combination treatment in Staphylococcus aureus","volume":"32","author":"Rodriguez de Evgrafov","year":"2015","journal-title":"Mol Biol Evol"},{"key":"2019101723585872200_bib27","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjmed.2006.04.001","article-title":"Pharmacodynamics: relation to antimicrobial resistance","volume":"119","author":"Rybak","year":"2006","journal-title":"Am J Med"},{"key":"2019101723585872200_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1469-0691.1997.tb00613.x","article-title":"Circumventing antibiotic resistance in specialized hospital units","volume":"3","author":"Sanders","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"2019101723585872200_bib29","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jss.2011.12.014","article-title":"A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit","volume":"176","author":"Sarraf-Yazdi","year":"2012","journal-title":"J Surg Res"},{"key":"2019101723585872200_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mimet.2009.07.017","article-title":"Variations in MIC value caused by differences in experimental protocol","volume":"79","author":"Schuurmans","year":"2009","journal-title":"J Microbiol Methods"},{"key":"2019101723585872200_bib31","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob Agents Ch"},{"key":"2019101723585872200_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2019101723585872200_bib33","first-page":"9","article-title":"Insights into newer antimicrobial agents against Gram-negative bacteria","volume":"9","author":"Taneja","year":"2016","journal-title":"Microbiology Insights"},{"key":"2019101723585872200_bib34","doi-asserted-by":"publisher","DOI":"10.1093\/femsle\/fnw210","article-title":"The risk of low concentrations of antibiotics in agriculture for resistance in human health care","volume":"363","author":"Ter Kuile","year":"2016","journal-title":"FEMS Microbiol Lett"},{"key":"2019101723585872200_bib35","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/ja400970n","article-title":"Reactions of the three AmpD enzymes of Pseudomonas aeruginosa","volume":"135","author":"Zhang","year":"2013","journal-title":"J Am Chem Soc"}],"container-title":["FEMS Microbiology Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femsle\/article-pdf\/364\/14\/fnx142\/30162208\/fnx142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femsle\/article-pdf\/364\/14\/fnx142\/30162208\/fnx142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T03:59:14Z","timestamp":1571371154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femsle\/article\/doi\/10.1093\/femsle\/fnx142\/3906681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/femsle\/fnx142","relation":{},"ISSN":["1574-6968"],"issn-type":[{"value":"1574-6968","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,6,30]]},"article-number":"fnx142"}}